Director, Lymphoma Program

Lymphoma Executive Committee Member, Sarah Cannon Research Institute

Associate Member, Colorado Blood Cancer Institute

Denver, CO

Join Dr. Michael Tees from the Colorado Blood Cancer Institute, as he discusses

Chimeric antigen receptor (CAR) T-cell therapy in 2024. Dr. Tees provides an overview of immunotherapy and approved indications, how to discuss treatment options with your patients, what to consider when referring patients for CAR T-cell therapy, how to prepare patients, and educating patients and caregivers about toxicity management. He also provides insight into the limitations of CAR-T therapy, as well as future directions. Tune in to this informative episode today to learn more!